Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Salubris Biotherapeutics Inc. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter suggests a focused approach to protecting technical innovations. The applicant is working to address this action to move the application toward issuance.
The examination process involves 1 distinct examiner and 1 distinct art unit. This indicates that the current intellectual property is concentrated within a specific technical classification at the patent office. The absence of multiple examiners or art units means that the prosecution process is streamlined, with a consistent set of standards being applied to the pending application.
CESARE, JOSEPH DAVID is identified as the busiest examiner for this portfolio. This examiner is responsible for the 1 busiest examiner pending office action. Since CESARE, JOSEPH DAVID handles the only active matter, this individual is the sole gatekeeper for the current patent goals. Practitioners should focus on the specific requirements and examination style of CESARE, JOSEPH DAVID to successfully resolve the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CESARE, JOSEPH DAVID | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18274668 | IL-15 FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME | CESARE, JOSEPH DAVID | 27d |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18274668 | IL-15 FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME | CESARE, JOSEPH DAVID | 1675 | §103§112 | Non-Final OA | 27d | Pending | Jul 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial